MediciNova (NASDAQ:MNOV) (NASDAQ: MNOV) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of small molecule therapeutics for serious and orphan diseases. The company’s core focus areas include neurological disorders, pulmonary diseases, fibrotic conditions and oncology. MediciNova’s lead candidates are designed to target key biological pathways such as neuroinflammation, fibrosis and aberrant cell signaling, with a strategy that combines in-house research capabilities and strategic partnerships to advance products through clinical development.
Among MediciNova’s most advanced programs is ibudilast (MN-166), a small molecule initially approved in Japan for asthma that is now under evaluation in the U.S. for progressive multiple sclerosis and amyotrophic lateral sclerosis. Another pivotal asset is seralutinib (formerly MN-172/MN-710), an inhaled kinase inhibitor being developed for pulmonary arterial hypertension, where it has received orphan drug designation. Tipelukast (MN-001) is also in development for fibrotic indications such as idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis, with licensing collaborations in place for select Asian markets. These programs reflect the company’s expertise in repurposing and optimizing known compounds for new therapeutic opportunities.
Founded in 1997 and headquartered in San Diego, California, MediciNova operates global R&D and clinical development teams while maintaining a presence in Tokyo through its Japanese subsidiary. The company has established strategic alliances and licensing agreements with leading pharmaceutical partners to facilitate regional development and potential commercialization. MediciNova’s international footprint extends to Europe, North America and Asia, enabling it to leverage multi-regional expertise and regulatory pathways in support of its clinical programs.
MediciNova is led by President and Chief Executive Officer Dr. Yoshihiro Ogasawara, who has more than two decades of experience in biopharmaceutical research and development. The broader leadership team brings together seasoned professionals in medicinal chemistry, clinical operations and regulatory affairs, underscoring the company’s commitment to advancing therapies that address high-unmet medical needs. Through a disciplined development strategy and collaborative approach, MediciNova aims to deliver innovative treatments to patients worldwide.
